Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.
MK-6194（一种旨在选择性激活调节性 T 细胞的 IL-2 突变体）的安全性、药代动力学和药效学：单次递增剂量和多次递增剂量试验数据
期刊:Immunohorizons
影响因子:
doi:10.1093/immhor/vlaf005
Scheid Johannes F, Cunningham-Bussel Kiki, Kim Nancy, Agarwal Shiuli, Nieddu Garrett, Cote Josee, Lemoine Lieselotte, Decaesteker Tatjana, Mendez Luis, Paul Erina, Love-Gregory Latisha, Contreras Alejandra Virginia, Zhao Xuemei, Franco-Dilone Lucia, Pang Ling, Baltus Gretchen A, Beaumont Maribel, Shah Ketal, Higginson-Scott Nathan, Kis-Toth Katalin, Otipoby Kevin L, Viney Joanne L, Sicard Eric, Rottey Sylvie, Sundy John S, Van Dyck Kristien, Laethem Tine, Larson Patrick, Sutradhar Santosh, Wnek Richard, Bueters Tjerk, Lai Eseng, Stoch S Aubrey, Iwamoto Marian, Robbins Jonathan A
